Navigation Links
Einstein researchers receive grants totaling $700,000 for innovative breast cancer research
Date:10/26/2007

(BRONX, NY) -- Three researchers at the Albert Einstein College of Medicine have been awarded grants from the Breast Cancer Research Foundation (BCRF). Drs. Thomas Rohan, Susan Horwitz and Rachel Hazan each received grants from the BCRF in its ongoing effort to support the advancement of breast cancer research. At the heart of the BCRFs generosity is its mission, which is to achieve prevention and a cure for breast cancer by providing critical funding for innovative clinical and genetic research at leading medical centers worldwide, while also increasing public awareness about good breast health.

Dr. Rohan, professor and chair of epidemiology and population health at Einstein, received $250,000 to carry out gene expression profilingusing so-called gene chipson women at risk of developing breast cancer. Using a technique that he and colleagues developed for extracting and storing RNA from breast tissue, Dr. Rohan will focus his efforts on women with benign breast disease (BDD), since women with this condition have an increased risk for breast cancer. For those BDD patients who eventually develop breast cancer, gene-expression profiles may help to predict clinical outcomes and identify those patients most likely to respond to therapy. Dr. Rohan and his colleagues have already established a multi-center cohort of more than 25,000 women who have undergone biopsies for BDD, and these breast tissue samples will be used in the study.

Dr. Horwitz, Falkenstein Professor of Cancer Research and co-chair of molecular pharmacology at Einstein, received $225,000 to study epigenetic changes (i.e., switching genes on and off in ways that dont involve changes in DNA sequence) in breast cancer cells that may help pinpoint why some breast tumors become drug-resistant. In particular, she will study whether epigenetic mechanisms cause cells to become resistant to Taxol, a drug she helped discover that has proven highly effective in treating breast cancer. Her work could lead to new drugs that reverse drug resistance and make breast tumors more sensitive to Taxol.

Dr. Hazan, associate professor of pathology at Einstein, received $225,000 to support her research effort to eradicate mestastasizing tumor cells. She will collaborate with Dr. Larry Norton of the Memorial Sloan-Kettering Cancer Center to determine the mechanism of action of the protein N-cadherin, which is produced by aggressive breast tumors and stimulates the spread of those tumors. The team will also look for potential drugs that can target this protein, with the ultimate aim of expanding the available options for treating late-stage breast cancer.


'/>"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Einstein researchers identify new way that bacteria develop resistance to antibiotics
2. Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell
3. Feinstein researchers identify intelligence gene
4. Study by Einstein researchers could lead to a novel strategy for treating obesity
5. Einstein researchers take the pulse of a gene in living cells
6. Einstein researchers demonstrate a novel approach to treating AIDS
7. Einsteins tea leaves inspire new blood separation technique
8. Researchers discover way to make cells in the eye sensitive to light
9. Researchers find how protein allows insects to detect and respond to pheromones
10. Researchers Uncover Key Step In Manufacture of Memory Protein
11. NYU researchers simulate molecular biological clock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... ... July 20, 2017 , ... Dr. Asher Kimchi, Founder and ... of the 2017 IAC Awards at the 22nd World Congress on Heart Disease held ... four faculty to receive the Distinguished Fellowship Awards. , Dr. Asher Kimchi, together with ...
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture Development™ ... board of directors. This addition continues to strengthen and diversify VIC’s board. , ... and Chairman. “He is a highly accomplished business executive with a broad range of ...
(Date:7/20/2017)... DENVER and PLYMOUTH, Minn., July 20, 2017 ... LLC , a personalized genetic evaluations company, today ... under their partnership investigating a genetic mutation implicated ... to extend the partnership for a second case ... Last year, the KCNQ2 Cure Alliance and Pairnomix ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... solution to make clinical trial sites and study participants truly unified. TrialKit, a ... compliant (FDA 21 CFR Part 11) research studies entirely on mobile devices. With ...
Breaking Biology Technology: